Navigation Links
MONOJECT Red/Yellow Mottled Stopper

ProductsMONOJECT Red/Yellow Mottled Stopper
Company Kendall Company
Item MONOJECT Red/Yellow Mottled Stopper
Features 
  • Fast clotting with thrombin silicone coated tubes
  • Laboratory procedures requiring fast clotting and serum - general chemistry and blood bank
  • Sterile tube interior
Description MONOJECT Red/Yellow Mottled Stopper
Info Kendall Company
Customer Service: (800) 962-9888
Web site: http://www.kendallhq.com

Related medicine products :

1. MONOJECT Blood Collection Needle and Tube Holders
2. MONOJECT CLEAR LABEL Lavender Stopper (for SYSMEX Analyzer)
3. MONOJECT Lavender Stopper (Liquid Additive)
4. MONOJECT Lavender Stopper (Powder Additive)
5. MONOJECT Pink Stopper
6. MONOJECT Blue Stopper
7. MONOJECT Green Stopper
8. MONOJECT Red Stopper (Non-Coated Tube)
9. MONOJECT CLEAR LABEL Red Stopper
10. MONOJECT Red Stopper (Silicone Coated Tube)
11. MONOJECT Royal Blue Stopper (Dry Additive)
High temp cauteries, fine tip micro....
Thru cut kerrison style punch 30 deg, 2.75 X 1.4 mm cut, 110 working length....
6 mm, 45 degree upwards, detachable....
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
Medicine Products:
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... current state of the global Sterilizers industry with a ... statistics on the market status of the Sterilizers manufacturers ... for companies and individuals interested in the industry. This ... its definition, applications and manufacturing technology. In this part, ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... Product liability lawsuits filed in the ... http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal court, ... in the U.S. District Court, Northern District of Ohio ... conference on January 7, 2015, at the Paul G. ... Palm Beach, Florida. The Conference is scheduled to begin ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... , , Medtronic Featured as Official ... The American Association of Heart Failure Nurses (AAHFN) is ... February 8-14 .   , The purpose of Heart Failure Awareness ... common and debilitating condition.  AAHFN will achieve this goal through the ...
... but effective treatment, experts say , FRIDAY, Feb. 5 ... can be killed by a type of bacteria that ... maggots to disinfect wounds (maggot debridement therapy) is standard ... dead tissue and ingest bacteria that are killed in ...
... responsible for ,pending epidemic, researchers say , FRIDAY, Feb. ... patients but can cause work-related injuries in surgeons, suggests ... Medicine researchers found that 87 percent of laparoscopic surgeons ... physical symptoms or discomfort. , "We face a pending ...
... NEW YORK , Feb. 5 Hospital for ... today announced its support of the Arthritis Foundation and Ad ... raise awareness of osteoarthritis, increase public health education and support ... our extensive clinical and research resources on raising awareness of ...
... , , BEIJING, CHINA , Feb. 5 ... attention to a certain previously released news announcements namely January 7 ... January 12,2010 , and January 22, 2010 . , These ... these events are now starting to crystallize and are beginning to transform ...
... more likely to misuse prescribed drugs, suffer flareups ... patients who use herbal remedies experience increased symptoms and ... Researchers followed 326 asthma patients for 33 months. Of ... and used prescribed inhaled corticosteroids (ICS) less often than ...
Cached Medicine News:Health News:AAHFN Promotes Heart Failure Awareness Week Through Webinar 2Health News:Wound-Healing Maggots Succumb to Deadly Bacteria 2Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 2Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 3Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 2Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 3Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 5Health News:Herbals Not the Answer for Asthma, Study Shows 2
(Date:12/24/2014)... Dec. 24, 2014  Novastem, a leader in ... patient in its study for ischemic stroke at ... Association, ischemic strokes account for 87 percent of ... patients in the study, entitled "Internal Research Protocol ... Mesenchymal Stem Cells and Intrathecal Administration of Neural ...
(Date:12/24/2014)... 24, 2014  Commonwealth Cornerstone Group (CCG) today announced the ... on Tuesday to help fund the expansion and consolidation of ... Sharon . PHN is the ... . It is the largest employer in ... people on staff. Currently, PHN Sharon offers scattered ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3